Multiclinic study of norfloxacin for treatment of urinary tract infections

Anthony J. Schaeffer*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

12 Scopus citations

Abstract

A multicenter open study of 477 patients with urinary tract infections was undertaken. The patients were treated with 400 mg of norfloxacin twice daily for seven to 30 days. Four hundred eight (98 percent) of 417 gram-negative organisms and 58 (94 percent) of 62 gram-positive organisms were susceptible to norfloxacin. The infecting organisms were eradicated in 276 of 307 evaluable patients (90 percent). Of the 31 bacteriologic failures, two organisms were initially resistant to norfloxacin and four organisms acquired resistance to norfloxacin and persisted despite treatment. Twenty-eight patients (10 percent) had recurrent infections; 24 of the 25 organisms involved in these infections were susceptible to norfloxacin. Seventeen patients (3.5 percent) experienced clinical adverse effects that were probably or definitely related to the drug. One adverse reaction was serious. Although norfloxacin was discontinued in two patients because of clinical side effects, none of the patients experienced laboratory adverse effects that were either serious or drug related.

Original languageEnglish (US)
Pages (from-to)53-58
Number of pages6
JournalThe American journal of medicine
Volume82
Issue number6 SUPPL. 2
DOIs
StatePublished - Jun 26 1987

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint Dive into the research topics of 'Multiclinic study of norfloxacin for treatment of urinary tract infections'. Together they form a unique fingerprint.

Cite this